Volume 26, Number 11—November 2020
Research Letter
Detection of SARS-CoV-2 in Hemodialysis Effluent of Patient with COVID-19 Pneumonia, Japan
Table
Day after symptom onset |
Hospitalization,
d |
Temperature, °C |
Event |
CRP, mg/dL |
Dialysis |
Specimens tested for SARS-CoV-2 by qRT-PCR‡ |
|||||
Medication† |
Nasal swab |
Blood |
Effluent, time collected |
||||||||
AZM |
Hydroxy |
1 h |
2 h |
||||||||
1 | 37.3 | ||||||||||
2 | 37.2 | ||||||||||
3 | 37.3 | ||||||||||
4 | 37.3 | Clinic | 18.8 (NA‡) | ||||||||
5 | 37.7 | ||||||||||
6 | 39.0 | ||||||||||
7 | 1 | 38.8 | Chest CT | N | N | 8.8 | – | ||||
8 | 2 | 38.4 | Y | Y | 9.0 | Y | 29.6 (1,080.6)§ | ND§ | 38.3 (157.91) | ND | |
9 | 3 | 38.7 | Y | Y | – | – | – | ||||
10 | 4 | 38.7 | Y | Y | 14.0 | – | – | ||||
11 | 5 | 37.4 | Chest CT | N | Y | 15.0 | Y | – | |||
12 | 6 | 37.0 | N | Y | – | – | – | ||||
13 | 7 | 37.2 | N | Y | – | – | – | ||||
14 | 8 | 37.0 | N | Y | – | – | – | ||||
15 | 9 | 36.9 | N | Y | 14.4 | Lixelle-DHP | – | ||||
16 | 10 | 37.0 | N | N | – | – | 34.3 (NA‡) | ||||
17 | 11 | 36.9 | N | N | – | Lixelle-DHP | ND | ||||
18 | 12 | 36.9 | N | N | 13.7 | – | ND | ||||
19 | 13 | 36.8 | N | N | – | – | – | ||||
20 | 14 | 36.6 | N | N | – | – | – | ||||
21 | 15 | 36.7 | N | N | 5.9 | Lixelle-DHP | – | ||||
22 | 16 | 36.7 | Chest CT, discharge | N | N | – | – | – |
*AZM, azithromycin; CRP, C-reactive protein; CT, computed tomography; Hydroxy, hydroxychloroquine; Lixelle-DHP, direct hemoperfusion using a β2 microglobulin adsorbent column; NA, not available; ND, not detected; qRT-PCR, quantitative reverse transcription-PCR; –, not done. †We prescribed azithromycin, 500 mg 2 times/d from day 1 to 3 because it was 1 of the potentially effective treatment regimens at the time. We also prescribed hydroxychloroquine 200 mg 2 times/d and initially planned to use it for 10 d in total, but the patient’s liver function tests (LFTs) became elevated during the course. We suspected side effects of hydroxychloroquine and stopped it on day 9. His LFTs returned to normal afterwards. ‡Results for SARS-CoV-2 shown as cycle threshold values (Viral load, copies/μL). Viral loads were not available because PCR was performed at an outside commercial laboratory where they did not report these results. The same PCR method was used (4) at both National Institute of Infectious Diseases (NIID), Japan, and the outside laboratory. HD effluent was collected at 1 hr and 2 hr into hemodialysis. §PCR test was performed at NIID, Japan where they report viral loads.
References
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. DOIPubMedGoogle Scholar
- Wang R, Liao C, He H, Hu C, Wei Z, Hong Z, et al. COVID-19 in hemodialysis patients: A report of 5 cases. Am J Kidney Dis. 2020;76:141–3. DOIPubMedGoogle Scholar
- US Centers for Disease Control and Prevention. Interim guidance for infection prevention and control recommendations for patients with suspected or confirmed COVID-19 in outpatient hemodialysis facilities 2020 Apr 21 [cited 2020 Apr 22]. https://www.cdc.gov/coronavirus/2019-ncov/healthcare-facilities/dialysis.html
- Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, et al. Development of genetic diagnostic methods for novel coronavirus 2019 (nCoV-2019) in Japan. Jpn J Infect Dis. 2020;73:304–7. DOIPubMedGoogle Scholar
- Lisowska KA, Dębska-Ślizień A, Jasiulewicz A, Heleniak Z, Bryl E, Witkowski JM. Hemodialysis affects phenotype and proliferation of CD4-positive T lymphocytes. J Clin Immunol. 2012;32:189–200. DOIPubMedGoogle Scholar
- Katagiri D, Ishikane M, Ogawa T, Kinoshita N, Katano H, Suzuki T, et al. Continuous renal replacement therapy for a patient with severe COVID-19. Blood Purif. 2020;11:1–3. DOIPubMedGoogle Scholar
- Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323:1843–4. DOIPubMedGoogle Scholar
- Tsuchida K, Yoshimura R, Nakatani T, Takemoto Y. Blood purification for critical illness: cytokines adsorption therapy. Ther Apher Dial. 2006;10:25–31. DOIPubMedGoogle Scholar
- van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382:1564–7. DOIPubMedGoogle Scholar
- US Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50(RR-5):1–43 .PubMedGoogle Scholar